Introduction: In this study, novel folic acid (FA)-modified curcumin (CUR) liposomes (LPs) were developed and evaluated for their antitumor activity in vitro and in vivo. Methods: Characterization of the LPs, including transmission electron microscopy, morphology, particle size, and zeta potential studies, was carried out. Drug entrapment efficiency, drug-loading capacity, and release properties in vitro were tested. The in vitro growth inhibition activity, cellular uptake efficiency, and cell apoptosis of FA-modified CUR LPs were also investigated by a cervical cancer HeLa cell model. Results: The optimized distearoyl-l-a-phosphatidylethanolamine (DSPE)-PEG 2000 -FA-LPs/CUR formed spherical vesicles of nanometer sizes and had particle sizes of 112.3±4.6 nm, polydispersity index of 0.19±0.03, and zeta potential of −15.3±1.4 mV. In addition, the EE% and DL% of (DSPE)-PEG 2000 -FA-LPs/CUR were 87.6% and 7.9%, respectively. Compared with the free drug, FAmodified CUR LPs had sustained-release properties in vitro. In vivo, a strong green fluorescence was observed in the cytoplasmic region after incubation of (DSPE)-PEG 2000 -FA-LPs/CUR for 2 hrs. Conclusion: (DSPE)-PEG 2000 -FA-LPs/CUR showed a superior antiproliferative effect on HeLa cells and had a better antitumor effect in vivo than the non-modified LPs. These results indicated that (DSPE)-PEG 2000 -FA-LPs/CUR was a promising candidate for antitumor drug delivery.
Introduction
Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth leading cause of cancer death in women. 1 In China, there are about 132,000 new cases of cervical cancer each year, accounting for 28% of the total number of new cases of cervical cancer worldwide. 2 At present, the most effective treatment for cervical cancer is achieved through a combination of cisplatin-based chemotherapy with radiation. 3 However, the clinical use of this combination treatment is limited because of several serious side effects, such as nephrotoxicity, neurotoxicity, hematological toxicity, chemoresistance, and offtarget damage to normal tissues. 4 In the early stages of the disease, this treatment regimen would result in a patient survival rate of 90%. However, the figure decreases to 17% among patients at advanced stages 5 due to the presence of chemoradioresistant cells. 6 Therefore, ongoing efforts are necessary for the development of new, effective therapeutic strategies to enhance chemotherapeutic efficacy and decrease these side effects, maximizing the local response and patient survival. Curcumin (CUR) is the chief component of the spice turmeric and is derived from the rhizome of the East Indian plant Curcuma longa. Curcuma longa is a member of the Zingiberacae (ginger) family of botanicals and is a perennial plant native to Southeast Asia. 7 It has low intrinsic toxicity and a wide range of pharmacological properties, including antitumor, anti-amyloid, antioxidant, and anti-inflammatory effects. Previous studies have shown that free CUR can induce cell cycle arrest and/or apoptosis and inhibit the activation of nuclear factor kappa B in different tumor cell lines. 8, 9 CUR has been associated with regression of premalignant lesions of the bladder, soft palate, gastrointestinal tract, cervix, and skin, with treatment responses in established malignancy. 10, 11 The only factor limiting the use of free CUR in the treatment of cancer is its poor solubility in water, which in turn limits the bioavailability of the system when administered orally. The reason for the treatment failure of CUR is most likely that the drug concentration in the body cannot reach the effective antitumor level. In addition, nonspecific binding capacity also decreases CUR concentration in tumor tissues. The application of liposomal formulations as carriers for anticancer drug modified by tumor-active-targeted ligand folate has been trialed and described in the literature in recent years. [12] [13] [14] [15] Folate conjugates can bind to the folate receptor (FR) with high affinity and enter the FR-elevated malignant cells by receptor-mediated endocytosis, 16, 17 and meanwhile avoid being endocytosed by those normal cells that express a low level of FRs. 18 Thus, adding folic acid (FA) to the distal ends of liposome (LP)-anchored PEG molecules can further improve tumor cell selectivity and the uptake efficiency of LPs. However, little research has been done on the pharmacodynamics of FA-modified CUR liposomal formulation. The aim of this study was to develop a novel FA-modified liposomal formulation that could exhibit efficient and stable encapsulation of CUR and therefore mediate its delivery to the solid tumor effectively and specifically. Characterization of the LPs, including transmission electron microscopy (TEM), morphology, particle size, and zeta potential, was carried out. Drug entrapment efficiency, drug-loading capacity, and release properties in vitro were tested. The in vitro growth inhibition activity, cellular uptake efficiency, and cell apoptosis of FA-modified CUR LPs were also investigated by a cervical cancer HeLa cell model. 
Materials and methods Materials

Animals
Experiments were carried out on rats weighing 220±20 g and Balb/c mice weighing 20±2 g. The animals were kept in cages in a room at a temperature of 25±2°C, with a 12:12 light-dark cycle. They had free access to food and water. All experiments were carried out in strict accordance with the experimental animal guidelines issued by the National Institutes of Health and approved by the Second Hospital of Anhui Medical University.
Preparation of LPs
FA-modified LPs containing CUR were prepared by the thin-film hydration method as described previously. 
Characterization
In order to determine the optimal parameters relative to the formulation of the (DSPE)-PEG 2000 -FA-LPs/CUR, drugloading (DL%), encapsulation efficiency (EE%), particle size, zeta potential, polydispersity index (PDI), and surface morphology of the LPs were measured. Dynamic light scattering (DLS; Zetasizer Nano ZS-90; Malvern Instruments, Malvern, UK) and transmission electron microscope (TEM; Tecnai G2 20; FEI, Memphis, TN, USA) were used for characterizing.
DL% and EE% were calculated as described earlier. 20 Firstly, CUR was extracted from LPs (20 mg) with 2 mL 5% glacial acetic acid: acetonitrile (55:45, v/v), and then the extracted solution was properly diluted prior to HPLC analysis. The content of CUR in the LPs was determined by the HPLC method. DL% and EE% were calculated according to Equations (1) and (2), respectively:
where W P is the weight of initial feeding polymer, W M is the weight of drug incorporated in LPs, and W F is the weight of initial feeding drug.
In vitro drug release 
Stability
The stability of (DSPE)-PEG 2000 -FA-LPs/CUR after storage at 4°C and 25°C for a period of 3 months was analyzed according to the ICH guidelines. The physical appearance, particle size, zeta potential, EE%, and DL% of the samples were analyzed over the 3-month period with an interval of 1 month.
In vitro anticancer activity assay
The in vitro anticancer activity of (DSPE)-PEG 2000 -FA-LPs /CUR on human cervical carcinoma HeLa cell line was evaluated by MTT assay. Nontoxic control l experiments were carried out using a complete growth culture medium. Briefly, cells were seeded into a 96-well plate at a density of 
DovePress
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A test , A control , and A blank represent the absorbance of cells with different treatments, untreated cells, and blank culture media, respectively. Each experiment was performed six times. Half-maximal inhibitory concentration (IC 50 ) was calculated for all samples by survival analysis using GraphPad Prism 5 software.
Cellular uptake
The cellular internalization of (DSPE)-PEG 2000 -FA-LPs /CUR, (DSPE)-PEG 2000 -LPs/CUR, CUR LPs, and free CUR was visualized by confocal microscopy using coumarin-6 as a fluorescent probe. HeLa cells were plated in six-well plates at 37°C under 5% CO 2 in folate-free RPMI 1640 medium containing 10% FBS. Hela cells were inoculated in a cell culture dish with 
Pharmacodynamics
Tumor reduction studies were conducted as reported earlier. 22 Female Balb/c mice aged 6-8 weeks were used for the experiment. 
Statistical analysis
All data points were denoted as mean ± SD. A two-tailed t-test or a one-way ANOVA was performed, respectively, when comparing two or more groups. Statistical significance was defined as P<0.05. Data were shown as mean ± SD.
Results and discussion
Preparation and characterization
In our current study, we designed FA-mediated stabilized liposomes encapsulating CUR to improve the therapeutic effect of CUR in the treatment of cervical cancer via the combination of active targeting and molecular targeting. A systematic approach was undertaken to develop and characterize preparation methods and liposome formulations in order to control drug leakage and thus maintain optimal drug loading inside the liposomes to increase the delivery of the drug to tumor tissues. CUR was encapsulated into FAmodified and nonmodified LPs using the thin-film hydration method. The obtained physicochemical properties of the formulations are summarized in Table 1 21 In addition, the EE% and DL% of (DSPE)-PEG 2000 -FA-LPs/CUR were 87.6% and 7.9%, respectively. Under the same loading conditions, ordinary CUR LPs and nonmodified LPs appeared to have higher EE% and DL% and smaller particle sizes; however, no relevant differences were observed in terms of these parameters among the three CUR LPs. In order to determine the influence of the CUR/lipid incubation ratio on loading, several ratios 
Stability
The stability of (DSPE)-PEG 2000 -FA-LPs/CUR was monitored by changes in physical appearance, particle size, zeta potential, EE%, and DL% during storage at 4°C and 25°C ( Table 2 ). The zeta potential exhibited little change over the 3-month storage, showing the stability of (DSPE)-PEG 2000 -FA -LPs/CUR. The results also indicated that during storage at 4°C or 25°C, no significant variation in physical appearance, particle size, EE%, and DL% was detected. It appears that the liposomal formulation showed excellent stability during storage, and no drug precipitation or liposome aggregation was observed throughout the 90 days.
In vitro drug release CUR release in vitro was also investigated using the dialysis method in PBS (pH 7.4) at 37°C for 24 hrs to examine the drug-release properties of LPs (Figure 3 ). Unlike the rapid release of free CUR, as predicted, three LP types, (DSPE)-PEG 2000 -FA-LPs/CUR, (DSPE)-PEG 2000 -LPs/CUR, and 
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Intensity (%) CUR LPs, exhibited similar gradual release properties under pH 7.4. Over time, all formulations of CUR LPs were released much more slowly than free drug. After 2 hrs, the cumulative release was about 86% in the free drug (CUR) and 30% in LPs. A biphasic release was observed in this case with a rapid release of about 30% in 2 hrs followed by sustained drug release of about 70% over 12 hrs. It suggested that in comparison with the free drug, (DSPE)-PEG 2000 -FALPs/CUR have sustained release properties. However, there was no significant difference among the three LPs in the release curve. The (DSPE)-PEG 2000 -FA-LPs/CUR was surfacecoated with the hydrophilic polymer PEG, which formed a hydrophilic barrier to prevent the accumulation of LPs and to improve their physical stability. In addition, phospholipid, the main ingredient used in this experiment, is a corrosive substance. Because of the poor water solubility of the drug, it is difficult for it to penetrate into the matrix of the LPs. The sustained release of the drug might mainly contribute to the corrosion rates of the LPs prepared with these phospholipids. After calculation, the in vitro drug-release kinetic model of (DSPE)-PEG 2000 -FA-LPs/CUR in release medium was found to fit well with the Higuchi equation: Q=9.523t1/2-1.231 (r=0.993). Thus, it was speculated that the sustainedrelease property of LPs could assist in decreasing drug leakage before drug-loaded systems arrived at the targeted tumors and cells.
In vitro anticancer activity assay
For anticancer effects in vitro, HeLa cells were treated with either (DSPE)-PEG 2000 -FA-LPs/CUR, (DSPE)-PEG 2000 -LPs /CUR, CUR LPs, or free CUR at different concentrations of the drug. Cells were then subjected to an MTT assay. The cell viability profile is presented in Figure 4 . As shown, a significant reduction in cell viability was observed in the (DSPE)-PEG 2000 -FA-LPs/CUR group, while the cytotoxicity of cells was clearly lower in the free CUR and (DSPE)-PEG 2000 -LPs/CUR groups. The negative control was represented by blank LPs, for which cell survival was 100%. From this result, we found that 1) the carrier material used in this study was safe and nontoxic; 2) as the CUR concentration increased, greater cell death was observed; 3) (DSPE)-PEG 2000 -FA-LPs/CUR showed a superior antiproliferative effect on HeLa cells, which may be expected to demonstrate obvious antitumor effect in vivo. After calculation, the IC 50 value of the (DSPE)-PEG 2000 -FA-LPs/CUR was found to be 0.45 µg/mL compared with a value of 0.82 µg/mL for (DSPE)-PEG 2000 -LPs/CUR, 1.47 µg/mL for free CUR, and 1.21 µg/ mL for CUR LPs (Figure 4 ). Blank LPs were tested as controls and did not induce significant cell death (data not shown). 
Pharmacodynamics
To assess the in vivo antitumor efficacy of (DSPE)-PEG 2000 -FA-LPs/CUR, human cervical cancer xenograft mice were employed. As shown in Figure 6 , all the treatment groups were better able to inhibit tumor growth and decrease tumor size compared with the control group. At the end of the experiment, tumors were found to be more sensitive to (DSPE)-PEG 2000 -FA-LPs/CUR at a volume of 77.3±56. 3) receptor ligand-mediated targeted delivery. H&E staining was used to determine whether there was organ damage. The results showed that there were no obvious lesions in heart, liver, spleen, lung, and kidney of the two groups, suggesting that (DSPE)-PEG 2000 -FA-LPs/CUR had no obvious acute toxicity in vivo ( Figure 6C ). We prepared a delivery system of FA-mediated liposomes with encapsulated CUR in this study. According to the results, the drug delivery system in our study was in an appropriate nanoscale size range, exhibited specific targets to tumor cells, and induced more cell death and cell apoptosis. These results suggested that (DSPE)-PEG 2000 -FA-LPs/CUR possessed the basic characteristics of targeted delivery systems and had the potency to improve the antitumor effects of CUR. 
